Mayfair Advisory Group’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$371K Sell
987
-8
-0.8% -$2.74K 0.11% 135
2026
Q1
$350K Sell
995
-31
-3% -$11.1K 0.12% 127
2025
Q4
$336K Sell
1,026
-69
-6% -$21.9K 0.13% 126
2025
Q3
$309K Sell
1,095
-3
-0.3% -$870 0.13% 133
2025
Q2
$316K Buy
1,098
+275
+33% +$77.9K 0.15% 123
2025
Q1
$256K Sell
823
-19
-2% -$5.61K 0.15% 131
2024
Q4
$219K Sell
842
-80
-9% -$23.7K 0.13% 145
2024
Q3
$295K Hold
922
0.19% 106
2024
Q2
$305K Buy
922
+6
+0.7% +$1.76K 0.21% 94
2024
Q1
$260K Buy
916
+19
+2% +$5.56K 0.19% 110
2023
Q4
$267K Hold
897
0.23% 98
2023
Q3
$243K Buy
+897
New +$224K 0.23% 96
2023
Q2
Sell
-897
Closed -$224K 126
2023
Q1
$224K Sell
897
-93
-9% -$22.8K 0.24% 99
2022
Q4
$267K Sell
990
-34
-3% -$9.11K 0.34% 87
2022
Q3
$236K Buy
1,024
+20
+2% +$4.85K 0.33% 90
2022
Q2
$248K Buy
1,004
+112
+13% +$27.4K 0.33% 89
2022
Q1
$217K Hold
892
0.28% 100
2021
Q4
$201K Buy
+892
New +$188K 0.27% 95
2020
Q4
Sell
-852
Closed -$217K 85
2020
Q3
$217K Buy
+852
New +$211K 0.56% 50

Other funds holding AMGN

Mayfair Advisory Group's AMGN Position: Q2 2026 in Review

Mayfair Advisory Group reduced its Amgen (AMGN) stake by 0.8% in Q2 2026, selling an estimated $2.74K and leaving 987 shares worth $371K. The position accounts for 0.11% of the portfolio, ranked #135.

Mayfair Advisory Group first reported a position in AMGN in Q3 2020 and has held it in 19 quarters since. 2,406 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Mayfair Advisory Group held 987 shares of Amgen worth $371K as of Q2 2026.
  • Mayfair Advisory Group sold 8 Amgen shares in Q2 2026, an estimated $2.74K.
  • Amgen made up 0.11% of Mayfair Advisory Group's portfolio in Q2 2026, its #135 holding.
  • Mayfair Advisory Group first reported a position in Amgen in Q3 2020 and has held it in 19 quarters since.
  • 2,406 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Mayfair Advisory Group's 13F filing for Q2 2026, filed 11 Aug 2026.